He added that the companies’ shared legacy of innovation in multispecific antibodies makes Genmab the right partner to take the program across the finish line.
A Signal to the Biotech Market
The deal also reverberated beyond the two companies. International Biotechnology Trust PLC, which counts Genmab among its portfolio companies, celebrated its 32nd M&A transaction since 2020. Portfolio managers Ailsa Craig and Marek Poszepczynski suggested the move underscores oncology’s dominant role in fueling biotech returns.
Their statement hinted at momentum: “Clusters of acquisition activity often emerge around key industry events. This could be the start of a welcome surge in deals.”
Legal Titans on the Field
The high-profile merger drew a who’s-who of international counsel. Genmab’s A&O Shearman team was spearheaded by Clare O’Brien and Derrick Lott, alongside a deep bench of partners including Harald Halbhuber, Michael Chernick, Jessica Delbaum, Jonathan Cheng, Doreen Lilienfeld, Matthew Brown, Christiaan de Brauw, Olivier Valk, and Rens Bondrager. Deal team details for the other firms remain under wraps.
